Clinical trials: Pancreatic Ductal Adenocarcinoma
Advanced Solid Tumors
TT-702 in Patients With Advanced Solid Tumours.
This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in…
- Trial name
- CURATE (NCT05272709)
- Testing
- TT-702, Anti-PD-1 and PD-L1 agent
- Where
- 3 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cancer Research UK
Neuroendocrine Tumor of Pancreas, Carcinoma, Pancreatic
Related Studies of Imaging Features and Prognosis Between Pancreatic Neuroendocrine Tumors and Pancreatic Cancer
1. Imaging findings (including CT and MRI images) of both well-differentiated G3 PNET and poorly differentiated PNET were studied; 2.
- Conditions
- Neuroendocrine Tumor of Pancreas, Carcinoma, Pancreatic, CT
- Trial name
- NCT04977596
- Testing
- No intervention
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Pancreatic Neoplasms, Pancreatic Adenocarcinoma
The Prognostic Impact of Extracapsular Lymph Node Involvement in Ductal Pancreatic Adenocarcinoma
Extracapsular lymph node involvement (ECLNI) has been identified as a pathological variable associated with worse outcome in esophageal, gastric and colorectal cancer.
- Trial name
- ECLNI DPAC (NCT00644254)
- Testing
- Pancreatic resection
- Where
- Belgium
- Volunteers
- 145 people
- Sponsor
- KU Leuven
Cancer Risk, Cancer Predisposition Syndrome
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member…
- Conditions
- Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors
- Trial name
- NCT05463796
- Testing
- Samples
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Carcinoma, Pancreatic Ductal
Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with relatively poor survival. Surgery is the first choice for the treatment of patients with early pancreatic cancer.
- Trial name
- NCT05723978
- Testing
- Selective extended dissection of pancreaticoduodenectomy
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Neoplasms Pancreatic
PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer
PRIMUS 002 is looking at 2 different chemotherapy regimens in the neo-adjuvant setting for pancreatic cancer. Each treatment will be given for 3 months prior to surgery
- Trial name
- PRIMUS002 (NCT04176952)
- Testing
- FOLFOX-A, AG
- Where
- 3 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Judith Dixon-Hughes
Carcinoma, Pancreatic Ductal
Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1)
PACAP-1 will evaluate to what extent an enhanced implementation of best practices in pancreatic cancer care leads to a prolonged survival and improvement of quality of life as compared to current practice.
- Trial name
- PACAP-1 (NCT03513705)
- Testing
- Best practices in pancreatic cancer care
- Where
- 17 sites in Netherlands
- Volunteers
- 4,000 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pancreatic Ductal Adenocarcinoma
Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease
The aim of this study is to assess whether prehabilitation supervised by an appropriate multimodality team improves indices of sarcopenia in patients scheduled to undergo pancreatoduodenectomy.
- Trial name
- SIPUP (NCT03770117)
- Testing
- Prehabilitation, Standard Procedure
- Where
- United Kingdom
- Volunteers
- 113 people
- Sponsor
- Manchester University NHS Foundation Trust
Pancreas Cancer
Pancreaticoduodenectomy in Elderly Pancreatic Ductal Adenocarcinoma Patients
We used the SEER database to analyze the data of patients with PDAC. The database includes patients of 18 registries in the USA from 1973-2013All the malignant cases were followed-up annually to determine vital status.
- Trial name
- NCT03659903
- Testing
- pancreaticoduodenectomy
- Volunteers
- 5,910 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Adenocarcinoma of the Pancreas
Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma
This is a clinical trial that tests a surgical treatment. Everyone in the study will get the same treatment, and there is no comparison or placebo group.
- Trial name
- PHOLIPANC (NCT07340151)
- Testing
- Surgical resection
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Pancreatic Ductal Adenocarcinoma
Impact of Multidisciplinary and Radiologic Review on Outcome of Pancreatic Cancer Patients: an Observational Study
The investigators compared two different time periods respectively before and after the application of a dedicated diagnostic and therapeutic protocol for pancreatic ductal adenocarcinoma including multidisciplinary discussion…
- Trial name
- RevRadPAC (NCT03973736)
- Testing
- application of a diagnostic and therapeutic protocol (multidisciplinary discussion and radiological CT review)
- Where
- Italy
- Volunteers
- 316 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Pancreatic Adenocarcinoma
Immunohistochemical Expression of PD-L1 in Pancreatic Ductal Adenocarcinoma
Pancreatic carcinoma is ranked the 11th most common cancer worldwide. It is a highly lethal malignant tumor. In Egypt, the disease has traditionally been considered rare, but population in the East Nile Delta region exhibits an…
- Trial name
- NCT05228808
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Pancreatic Ductal Adenocarcinoma
Radiomics Based on Multimodal Imaging in Predicting Staging and Prognosis of Pancreatic Cancer
Retrospectively analyzed radiomics features of pancreatic ductal adenocarcinoma to predict staging and prognosis
- Trial name
- NCT04954378
- Testing
- radiomics
- Volunteers
- 300 people
- Sponsor
- Peking University Third Hospital
Pancreatic Cyst, Pancreatic Neuroendocrine Carcinoma
Diagnosis of PCL With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy
Pancreatic cystic lesions (PCLs) comprise of a heterogeneous group of entities that are benign, premalignant or malignant. With increased use of modern imaging techniques in recent years, incidentally discovered PCL have become…
- Conditions
- Pancreatic Cyst, Pancreatic Neuroendocrine Carcinoma, Pancreatic Pseudocyst, Pancreatic Serous Cystadenoma
- Trial name
- NCT03884179
- Volunteers
- 58 people
- Sponsor
- Sahlgrenska University Hospital
Neoplasms Pancreatic
A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma
The AJCC TNM staging system is the prevailing method in prognostic evaluation of pancreatic ductal adenocarcinoma (PDAC) at present , but it did not include factors such as the tumor immune microenvironment that are known to…
- Trial name
- NCT05547074
- Testing
- pancreatic cancer surgery
- Where
- China
- Volunteers
- 302 people
- Sponsor
- Zhejiang University
Pancreatic Ductal Adenocarcinoma
Survival Among Patients With Pancreatic Cancer Depending on Surgical Resection Rate
The primary aim of this population-based study is to investigate how a high resection rate of pancreaticoduodenectomy affects overall survival among patients aged ≥70 years with pancreatic ductal adenocarcinoma.
- Trial name
- NCT04802993
- Testing
- Resection rates
- Volunteers
- 5,123 people
- Sponsor
- Linkoeping University
Colorectal Carcinoma, Endometrial Carcinoma
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory).
- Conditions
- Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma
- Trial name
- NCT04851119
- Testing
- Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint
- Where
- 21 sites in United States
- Volunteers
- 147 people
- Sponsor
- Children's Oncology Group
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Pancreatic Cancer Recurrence in the Netherlands
The aim of this nationwide, observational cohort study is to evaluate current surveillance strategies after primary resection of pancreatic ductal adenocarcinoma (PDAC) in the Netherlands, with regard to the detection, treatment…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer, PDAC
- Trial name
- NCT04605237
- Where
- Netherlands
- Volunteers
- 1,750 people
- Sponsor
- UMC Utrecht
Pancreatic Cancer, Ampullary Cancer
Recurrence After Whipple's (RAW) Study
Pancreatic head malignancies are aggressive cancers that are often inoperable when they are diagnosed. In the ~20% of patients who are diagnosed when the disease is still operable, surgery is the only treatment that can provide a…
- Conditions
- Pancreatic Cancer, Ampullary Cancer, Bile Duct Cancer, Cholangiocarcinoma, Extrahepatic
- Trial name
- NCT04596865
- Testing
- Pancreaticoduodenectomy
- Where
- 29 sites in Australia, Austria and 6 more
- Volunteers
- 1,484 people
- Sponsor
- University Hospital Plymouth NHS Trust